Inoviv has secured significant funding from venture capital firm Hoxton Ventures and leading investment manager Foresight Group to expand the delivery of highly accurate, fully quantitative targeted biomarker workflows and panels. This latest investment will enable Inoviv to further expand its commercial activities to support the pharmaceutical and biotech space in support of clinical proteomics, including clinical trial monitoring, while also extending R&D capacity and innovation to address the fast-growing biomarker market and accelerate the development and approval of life-changing therapeutics.